Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Carlos S. Vallejos"'
Autor:
Carlos S. Vallejos-Sologuren
Publikováno v:
Diagnóstico. 59:77-85
El cáncer es uno de los problemas de salud pública en muchos países o regiones del mundo. La incidencia, mortalidad y la prevalencia del cáncer, permiten cuantificar la magnitud de esta patología y orientan las políticas públicas en relación
Autor:
Ben Ingram, Daniel G. Neary, Pablo Garcia-Chevesich, Romina Mendoza Mendoza, Juan Pino, Carlos S. Vallejos, Claudia Sangüesa, Alfredo Ibáñez, Felipe Pérez, Roberto Pizarro, Juan Pablo Flores V, Jonathan O. Sharp
Publikováno v:
River Research and Applications. 36:1828-1837
Autor:
Maria Rowena Del Rosario-Raymundo, Gary Dubin, Céline Bouchard, Jorge Salmerón, Margaret E. Cruickshank, Frank Struyf, Tanya Stoney, Shelly A. McNeil, Xavier Castellsagué, Marie Cecile Bozonnat, Alison Fiander, Galina Minkina, Bram ter Harmsel, Alevtina Savicheva, Suzanne M. Garland, Deborah Money, Arunachalam Ilancheran, Mark G. Martens, Carlos S. Vallejos, Dominique Rosillon, Timothy Yong Kuei Lim, Kah Leng Fong, Cosette M. Wheeler, S R Skinner, Eduardo Lazcano-Ponce, Laurence Baril, Archana Chatterjee, Swee Chong Quek
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as def
Autor:
Christian Caglevic, Zaida Morante, Alfredo Aguilar, Joseph A. Pinto, Cynthia Villarreal-Garza, Claudio Flores, Ana M. Posada, Franz Usuga, Williams Fajardo, Pamela Rebaza, Marcia Carrasco, Indira Tirado-Hurtado, Gerson Mejia, Manuel V Villarán, Carlos S. Vallejos, Luis Pinillos
Publikováno v:
ecancermedicalscience
Breast cancer (BC) is a highly prevalent malignancy in Latin American women, most cases being diagnosed at locally advanced or metastatic stages when options for cancer care are limited. Despite its label as a public health problem in the region, Lat
Autor:
Carlos S. Vallejos, Paola Montenegro, Luis Pinillos, Joseph A. Pinto, Frank Young, Indira Tirado-Hurtado, Alfredo Aguilar
Publikováno v:
Critical Reviews in Oncology/Hematology
COVID-19 pandemic is the more challenging public health emergency of the century, producing the collapse of health systems and unprecedented levels of morbidity and mortality around the world, especially in low resource settings. Patients with chroni
Autor:
Bram ter Harmsel, Suzanne M. Garland, P.V. Suryakiran, Shelly A. McNeil, Archana Chatterjee, Karin Hardt, Yong Kuei Timothy Lim, Cosette M. Wheeler, Alevtina Savicheva, Nahida Chakhtoura, S. Rachel Skinner, Henry C Kitchener, Wim Quint, Dominique Descamps, Tanya Stoney, Kah Leng Fong, V. N. Prilepskaya, Swee Chong Quek, Brecht Geeraerts, Mark G. Martens, Carlos S. Vallejos, Eduardo Lazcano-Ponce, Murdo Ferguson, M. Rowena Del Rosario-Raymundo, Anco Molijn, Galina Minkina, Gary Dubin, Céline Bouchard, Naveen Karkada, Deborah Money, Barbara Romanowski, Jack T. Stapleton, Jorge Salmerón, Margaret E. Cruickshank, Frank Struyf, Daniel da Silva
Publikováno v:
The Lancet Infectious Diseases. 16:1154-1168
Summary Background Although the risk of human papillomavirus (HPV) infection is greatest in young women, women older than 25 years remain at risk. We present data from the VIVIANE study of the HPV 16/18 AS04-adjuvanted vaccine in adult women after 7
Autor:
Deborah Money, S. Rachel Skinner, Myron J. Levin, Frank Struyf, Dominique Rosillon, M. Rowena Del Rosario-Raymundo, Daniel da Silva, Galina Minkina, Gary Dubin, Xavier Castellsagué, Romanenko Vv, Irina Gogotadze, Suzanne M. Garland, Brecht Geeraerts, V. N. Prilepskaya, Cosette M. Wheeler, Carlos S. Vallejos, Shelly A. McNeil, Eduardo Lazcano-Ponce, Laurence Baril, Marie Cecile Bozonnat, Archana Chatterjee, Diane M. Harper, Barbara Romanowski
Publikováno v:
International Journal of Cancer. 138:2428-2438
The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk of progression from cervical HPV infection to detectable cervical intraepithelial ne
Autor:
Rodrigo Valdés-Pineda, Claudia Sangüesa, Ben Ingram, Roberto Pizarro-Tapia, Fernando González-Leiva, Carlos S. Vallejos
Publikováno v:
Water
Volume 12
Issue 7
Water, Vol 12, Iss 1887, p 1887 (2020)
Volume 12
Issue 7
Water, Vol 12, Iss 1887, p 1887 (2020)
To develop intensity-duration-frequency (IDF) curves, it is necessary to calculate annual maximum rainfall intensities for different durations. Traditionally, these intensities have been calculated from the analysis of traces recorded by rain gauges
Autor:
Oscar Arrieta, Christian Rolfo, Gilberto Lopes, Edgardo S. Santos, Zyanya Lucia Zatarain-Barrón, Andrés F. Cardona, Luis E. Raez, Carlos S. Vallejos, Luis Mas, Christian Caglevic, Heath W. Catoe, Carlos H. Barrios
Publikováno v:
Lung cancer: journal of the International Association for the Study of Lung Cancer
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Lung cancer is a public health problem worldwide and Latin America (LATAM) cannot escape this reality. This malignant disease has not only a high prevalence in the region, but is also the main cause of cancer related deaths, and in other emerging cou
Autor:
Janine M. Lombard, Agustin A. Garcia, Halle C. F. Moore, Frances M. Boyle, Prudence A. Francis, Carol J. Fabian, Shaker R. Dakhil, Carlos S. Vallejos, John F. Forbes, Henry L. Gomez, Kathy S. Albain, David L. Porter, Ann H. Partridge, Silvana Martino, Gabriel N. Hortobagyi, Lori M. Minasian, Joseph M. Unger, Richard D. Gelber, Frank L. Meyskens, Lori J. Goldstein, Erika Hitre, Julie R. Gralow, Kelly-Anne Phillips, William E. Barlow
Publikováno v:
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New England Journal of Medicine, 372(10), 923-932. doi: 10.1056/NEJMoa1413204. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/49n0z7zv
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Obstetrical and Gynecological Survey, 70(6), 392-393. doi: 10.1097/01.ogx.0000467230.21869.a4. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5d37s9m3
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Obstetrical and Gynecological Survey, 70(6), 392-393. doi: 10.1097/01.ogx.0000467230.21869.a4. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5d37s9m3
Copyright © 2015 Massachusetts Medical Society. BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin- releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack